Affimed Revenue 2014-2024 | AFMDQ
Affimed revenue from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Affimed Annual Revenue
(Millions of US $) |
| 2023 |
$9 |
| 2022 |
$44 |
| 2021 |
$48 |
| 2020 |
$32 |
| 2019 |
$24 |
| 2018 |
$28 |
| 2017 |
$2 |
| 2016 |
$7 |
| 2015 |
$8 |
| 2014 |
$4 |
| 2013 |
$7 |
| 2012 |
$2 |
Affimed Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$0 |
| 2024-06-30 |
$0 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$12 |
| 2022-09-30 |
$15 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$9 |
| 2021-12-31 |
$12 |
| 2021-09-30 |
$10 |
| 2021-06-30 |
$12 |
| 2021-03-31 |
$14 |
| 2020-12-31 |
$11 |
| 2020-09-30 |
$12 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$6 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
$13 |
| 2018-12-31 |
$27 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$1 |
| 2017-06-30 |
$1 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$1 |
| 2016-09-30 |
$1 |
| 2016-06-30 |
$2 |
| 2016-03-31 |
$2 |
| 2015-12-31 |
$2 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$3 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$1 |
| 2013-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
